Cameroon has successfully stopped mass drug administration (MDA) for lymphatic filariasis in the country following the likely interruption of transmission in all 142 endemic districts as of FY22 (October 2021 – September 2022).
Cameroon has completed the required number of rounds of MDA in the last three districts requiring treatment. Cameroon is planning "TIS+" (trachoma impact surveys with serology/PCR) in February 2024. Cameroon is also working on its trachoma elimination dossier.
The NTDP plans to conduct OEM and pre-Stop MDA for onchocerciasis in 2024 and then develop plans for further assessments in FY2024.
Standard Disease-Specific Indicators as of FY21
FY21 is October 2020 through September 2021
of ever-endemic districts have stopped MDA as of FY21
(i.e. have passed stop MDA survey, TAS1 (First Transmission Assessment Survey))*
* MDA has stopped for LF in all districts in Cameroon except one
of ever-endemic districts in post-surveillance phase as of FY21
(i.e. have passed last surveillance survey, TAS3 (third Transmission Assessment Survey))
of persons no longer at risk as of FY21 among those who were ever at risk
of ever-endemic districts have stopped MDA as of FY21
(i.e. have passed stop MDA survey, TIS (Trachoma Impact Survey))
of ever-endemic districts in post-MDA surveillance phase as of FY21
(i.e. have passed surveillance survey, TSS (Trachoma Surveillance Survey))
of persons no longer at risk as of FY21 among those who were ever at risk
of ever endemic districts have been treated at least once as of FY21
(in cases where a country has more treated districts reported than, ever endemic, the adjusted percent is 100%)